Inhibiting HIF1α and LGMN enhances CD8+ T cell- anti-tumor immunity, impairs GBM tumor progression, and improves immunotherapy responses (anti-PD1 therapy) in mice (32). The gene discussed is CD8A; the disease is neoplasm.